Free Trial
→ The 1934 playbook (From American Alternative) (Ad)tc pixel Free BLFS Stock Alerts

BioLife Solutions (BLFS) Financials

BioLife Solutions logo
$24.24 +0.22 (+0.89%)
As of 01:27 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for BioLife Solutions

Annual Income Statements for BioLife Solutions

This table shows BioLife Solutions' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -4.21 -6.88 -2.73 -25 -1.66 1.98 -8.91 -140 -68 -20 -4.60
Consolidated Net Income / (Loss)		 -5.00 -8.04 -2.52 -25 -1.66 1.98 -8.91 -140 -68 -20 -4.60
Net Income / (Loss) Continuing Operations		 -5.00 -8.04 -2.52 -25 -1.66 1.98 -8.91 0.39 -12 -8.79 -12
Total Pre-Tax Income 		-5.00 -8.04 -2.52 -25 -3.20 -1.28 -29 -4.85 -12 -8.82 -12
Total Operating Income		 -5.02 -4.85 -1.06 3.66 -0.22 -6.24 -35 -5.92 -17 -4.48 -17
Total Gross Profit		 3.81 4.78 6.75 14 19 27 37 47 41 50 62
Total Revenue		 6.45 8.23 11 20 27 48 119 76 68 75 96
Operating Revenue		 6.45 8.23 11 20 27 48 119 76 68 75 96
Total Cost of Revenue		 2.63 3.45 4.28 6.22 8.76 21 82 29 27 25 34
Operating Cost of Revenue		 2.63 3.45 4.28 6.22 8.76 21 82 29 27 25 34
Total Operating Expenses		 8.83 9.63 7.80 9.86 19 34 72 53 59 55 79
Selling, General & Admin Expense		 4.87 4.59 4.52 5.95 8.89 15 34 33 43 41 46
Marketing Expense		 2.58 3.01 2.09 2.62 4.70 6.41 14 12 11 8.93 9.85
Research & Development Expense		 1.38 2.03 1.19 1.30 3.17 6.72 12 8.67 5.52 4.75 7.57
Amortization Expense		 - - - 0.00 1.08 3.03 8.20 3.99 1.03 0.26 0.26
Other Operating Expenses / (Income)		 - - - - - - - - 0.00 0.00 16
Other Special Charges / (Income)		 - - - 0.00 0.05 1.58 2.88 -4.75 -2.19 0.00 0.00
Total Other Income / (Expense), net		 0.02 -3.19 -1.46 -29 -2.98 4.96 6.13 1.08 4.98 -4.35 4.52
Interest & Investment Income		 0.00 -2.79 -1.01 -0.39 9.87 1.36 5.97 0.41 -1.41 -4.84 2.71
Other Income / (Expense), net		 0.02 0.00 -0.11 -28 13 3.60 0.17 0.66 6.39 0.49 1.82
Income Tax Expense		 - - 0.00 0.00 -1.54 -3.26 -20 -5.24 -0.06 -0.04 0.05
Net Income / (Loss) Discontinued Operations		 - - - - - - - -140 -56 -11 7.54
Basic Earnings per Share		 ($0.35) ($0.54) ($0.21) ($1.56) ($0.09) $0.07 ($0.23) ($3.29) ($1.55) ($0.44) ($0.09)
Weighted Average Basic Shares Outstanding		 12.18M 12.64M 13.26M 16.26M 19.46M 27.31M 38.50M 42.48M 43.72M 46.07M 47.75M
Diluted Earnings per Share		 ($0.35) ($0.54) ($0.21) ($1.56) ($0.09) ($0.06) ($0.23) ($3.25) ($1.55) ($0.44) ($0.10)
Weighted Average Diluted Shares Outstanding		 12.18M 12.64M 13.26M 16.26M 19.46M 27.31M 38.50M 43.07M 43.72M 46.07M 48.65M
Weighted Average Basic & Diluted Shares Outstanding		 12.18M 12.64M 13.26M 16.26M 19.46M 27.31M 38.50M 43.21M 45.30M 47M 48.30M

Quarterly Income Statements for BioLife Solutions

This table shows BioLife Solutions' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -29 -15 -10 -21 -1.70 12 -0.45 -16 0.62 11 1.19
Consolidated Net Income / (Loss)		 -29 -15 -10 -21 -1.70 12 -0.45 -16 0.62 11 1.19
Net Income / (Loss) Continuing Operations		 -16 17 -3.20 -5.56 -0.47 7.68 0.27 -16 0.62 3.54 1.19
Total Pre-Tax Income 		-16 16 -3.18 -5.56 -0.55 7.54 0.29 -16 0.70 3.36 1.25
Total Operating Income		 -15 16 -3.30 -1.31 -0.42 7.35 -0.50 -17 -0.09 1.35 0.03
Total Gross Profit		 12 8.88 12 13 14 9.92 15 16 18 12 17
Total Revenue		 24 -15 18 20 21 -8.37 22 25 28 19 28
Operating Revenue		 24 -15 18 20 21 -8.37 22 25 28 19 28
Total Cost of Revenue		 12 -24 6.19 6.51 7.40 -18 7.25 8.99 10 6.81 10
Operating Cost of Revenue		 12 -24 6.19 6.51 7.40 -18 7.25 8.99 10 6.81 10
Total Operating Expenses		 27 -7.39 16 15 14 2.57 15 33 18 11 17
Selling, General & Admin Expense		 11 4.07 10 9.32 9.33 5.36 11 11 12 11 12
Marketing Expense		 4.88 -2.47 2.38 2.48 2.51 -2.51 2.44 2.73 2.53 1.99 2.53
Research & Development Expense		 3.74 0.39 2.08 2.03 1.89 -0.05 1.44 2.72 2.71 -0.07 2.65
Amortization Expense		 1.31 -0.66 0.69 0.68 0.68 0.00 0.07 0.71 0.70 -1.85 0.09
Total Other Income / (Expense), net		 -0.21 0.09 0.11 -4.25 -0.13 0.19 0.78 0.93 0.79 2.01 1.22
Interest & Investment Income		 -0.45 -0.20 -0.14 -4.40 -0.23 0.12 0.68 0.68 0.51 0.83 1.04
Other Income / (Expense), net		 0.24 0.29 0.25 0.15 0.10 0.07 0.10 0.25 0.28 1.18 0.18
Income Tax Expense		 0.12 -0.23 0.02 0.00 -0.08 -0.14 0.01 0.13 0.08 -0.17 0.06
Basic Earnings per Share		 ($0.67) ($0.33) ($0.22) ($0.45) ($0.04) $0.27 ($0.01) ($0.33) $0.01 $0.24 $0.02
Weighted Average Basic Shares Outstanding		 14.44M 43.72M 35.21M 25.29M 46.18M 46.07M 47.13M 31.96M 47.93M 47.75M 48.46M
Diluted Earnings per Share		 ($0.67) ($0.33) ($0.22) ($0.45) ($0.04) $0.27 $0.00 ($0.33) $0.01 $0.23 $0.02
Weighted Average Diluted Shares Outstanding		 43.57M 43.72M 45.43M 25.29M 46.18M 46.07M 48.37M 31.96M 48.72M 48.65M 49.25M
Weighted Average Basic & Diluted Shares Outstanding		 44.03M 45.30M 46.03M 46.14M 46.39M 47M 47.56M 47.91M 48.15M 48.30M 48.86M

Annual Cash Flow Statements for BioLife Solutions

This table details how cash moves in and out of BioLife Solutions' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.37 -0.77 5.26 24 -15 84 -21 -50 16 60 -62
Net Cash From Operating Activities		 -4.97 -4.33 0.61 2.35 1.21 6.65 -4.59 -8.49 -12 8.43 20
Net Cash From Continuing Operating Activities		 -4.97 -4.33 0.61 2.35 11 6.65 -4.59 -8.49 -12 8.43 20
Net Income / (Loss) Continuing Operations		 -5.00 -8.04 -2.52 -25 -1.66 1.98 -8.91 -140 -68 -20 -4.60
Consolidated Net Income / (Loss)		 -5.00 -8.04 -2.52 -25 -1.66 1.98 -8.91 -140 -68 -20 -4.60
Depreciation Expense		 0.34 0.37 0.34 0.34 0.72 2.04 4.66 6.78 7.11 5.16 2.25
Amortization Expense		 -0.04 0.09 0.03 0.00 1.08 3.03 8.32 9.27 3.93 3.03 1.70
Non-Cash Adjustments To Reconcile Net Income		 0.55 3.81 2.45 30 16 2.17 19 140 45 18 30
Changes in Operating Assets and Liabilities, net		 -0.83 -0.56 0.30 -3.22 -5.24 -2.58 -28 -25 -0.79 2.57 -8.84
Net Cash From Investing Activities		 4.24 0.39 -0.14 -6.50 -27 -25 -13 -58 18 58 -72
Net Cash From Continuing Investing Activities		 4.24 0.39 -0.14 -6.50 -27 -25 -13 -58 18 58 -72
Purchase of Property, Plant & Equipment		 -1.42 -1.26 -0.14 -0.50 -0.68 -1.96 -8.39 -10 -6.38 -3.23 -9.48
Acquisitions		 - - - -6.00 -23 -15 - 0.00 0.00 -0.30 -10
Purchase of Investments		 -1.41 - 0.00 0.00 -1.00 0.00 0.00 -53 -27 -18 -114
Divestitures		 - - - - 1.25 0.00 1.56 0.00 0.00 73 24
Sale and/or Maturity of Investments		 7.07 1.65 - - - 0.00 0.00 8.92 56 22 42
Other Investing Activities, net		 - - - 0.00 -3.16 -7.84 -6.37 -3.54 -4.86 -15 -2.89
Net Cash From Financing Activities		 0.37 3.17 4.80 28 1.60 102 -2.78 16 11 -6.78 -11
Net Cash From Continuing Financing Activities		 0.37 3.17 4.80 28 1.60 96 -2.78 16 11 -6.78 -11
Repayment of Debt		 0.00 0.00 -0.01 -0.07 -0.16 -2.23 -32 -2.50 -0.43 -6.68 -9.97
Issuance of Common Equity		 - - 0.00 20 0.00 100 0.00 0.00 10 0.00 0.00
Other Financing Activities, net		 0.37 0.28 3.97 13 1.76 1.03 0.39 -1.05 0.78 -0.10 -0.96
Other Net Changes in Cash		 - - - - - - - -0.11 0.04 0.00 0.00
Cash Interest Paid		 - - - - 0.00 0.00 0.45 0.59 1.93 1.61 0.76

Quarterly Cash Flow Statements for BioLife Solutions

This table details how cash moves in and out of BioLife Solutions' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -2.11 16 -5.65 -7.68 2.08 71 -28 -35 -2.42 3.56 -10
Net Cash From Operating Activities		 -4.38 2.31 -4.48 6.46 4.80 1.65 1.73 7.37 6.10 4.92 -0.49
Net Cash From Continuing Operating Activities		 -4.38 2.31 -4.48 6.46 4.80 1.65 1.73 7.37 6.10 4.92 -0.49
Net Income / (Loss) Continuing Operations		 -29 -15 -10 -21 -1.70 12 -0.45 -16 0.62 11 1.19
Consolidated Net Income / (Loss)		 -29 -15 -10 -21 -1.70 12 -0.45 -16 0.62 11 1.19
Depreciation Expense		 1.92 1.47 1.36 1.45 1.41 0.94 0.68 0.67 0.64 0.26 0.37
Amortization Expense		 1.05 0.70 0.73 0.77 0.82 0.70 0.60 0.51 0.47 0.12 0.20
Non-Cash Adjustments To Reconcile Net Income		 25 11 8.68 22 4.46 -15 4.83 22 4.35 -1.72 7.84
Changes in Operating Assets and Liabilities, net		 -3.42 3.68 -5.03 3.13 -0.18 2.18 -3.94 -0.11 0.03 -4.82 -10
Net Cash From Investing Activities		 1.66 3.96 -0.22 -13 -1.68 74 -27 -40 -5.97 1.14 -1.83
Net Cash From Continuing Investing Activities		 1.66 3.96 -0.22 -13 -1.68 74 -27 -40 -5.97 1.14 -1.83
Purchase of Property, Plant & Equipment		 -1.50 -0.98 -0.36 -1.00 -1.11 -0.76 -0.18 -1.74 -3.30 -4.26 -0.17
Purchase of Investments		 -6.96 -4.41 -6.37 -4.34 -5.30 -2.40 -30 -34 -13 -37 -20
Sale and/or Maturity of Investments		 11 11 6.97 6.07 5.17 3.71 3.57 6.57 13 19 19
Other Investing Activities, net		 -0.90 -1.40 -0.46 -14 -0.43 -0.04 -0.25 -0.16 -2.37 -0.10 0.00
Net Cash From Financing Activities		 0.61 9.84 -0.95 -0.70 -1.04 -4.09 -2.99 -2.88 -2.56 -2.50 -7.90
Net Cash From Continuing Financing Activities		 0.61 9.84 -0.95 -0.70 -1.04 -4.09 -2.99 -2.88 -2.56 -2.50 -7.90
Repayment of Debt		 -0.33 0.17 -0.23 -0.28 -2.70 -3.48 -2.49 -2.49 -2.49 -2.50 -2.50
Other Financing Activities, net		 0.94 -0.58 -0.73 -0.43 1.66 -0.60 -0.50 -0.39 -0.07 - -5.40
Cash Interest Paid		 0.46 0.53 0.45 0.38 0.41 0.37 0.27 0.22 0.16 0.12 0.07

Annual Balance Sheets for BioLife Solutions

This table presents BioLife Solutions' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 12 7.93 12 45 93 235 554 450 413 399 406
Total Current Assets		 6.97 4.63 9.93 38 24 115 126 138 121 149 137
Cash & Equivalents		 2.17 1.41 6.66 31 6.45 90 70 19 28 92 33
Short-Term Investments		 1.65 - - - - - 0.00 43 16 9.20 56
Accounts Receivable		 0.93 1.19 1.02 3.05 5.35 8.01 23 34 7.90 8.48 7.95
Inventories, net		 1.83 1.76 1.85 3.51 11 12 28 35 27 29 30
Prepaid Expenses		 0.38 0.27 0.40 0.35 1.35 4.65 4.66 6.88 4.67 5.95 9.53
Plant, Property, & Equipment, net		 1.45 1.19 1.11 1.32 5.57 10 18 24 5.69 5.97 15
Total Noncurrent Assets		 3.95 2.11 1.11 6.58 63 110 411 288 286 245 255
Long-Term Investments		 - - 1.07 6.55 2.50 5.87 4.37 6.40 5.62 1.00 31
Goodwill		 - - - 0.00 34 58 225 225 212 209 209
Intangible Assets		 2.22 - - 0.00 22 31 152 32 12 5.57 4.26
Other Noncurrent Operating Assets		 1.73 2.11 0.04 0.04 5.01 15 29 25 14 16 11
Total Liabilities & Shareholders' Equity		 12 7.93 12 45 93 235 554 450 413 399 406
Total Liabilities		 2.51 4.76 2.05 31 49 30 76 86 75 51 34
Total Current Liabilities		 1.73 1.13 1.51 1.94 7.67 16 43 45 42 33 23
Short-Term Debt		 - - - 0.00 0.38 3.25 5.99 3.95 6.29 11 5.00
Accounts Payable		 1.03 0.71 0.69 0.72 3.12 3.67 15 15 2.27 3.36 1.49
Accrued Expenses		 0.15 0.12 0.20 1.22 3.37 4.76 16 18 9.12 12 12
Current Deferred & Payable Income Tax Liabilities		 - - - - - - 2.59 4.15 4.40 4.23 2.28
Other Current Liabilities		 - - - 0.00 0.80 3.90 2.91 3.02 1.29 1.46 2.24
Total Noncurrent Liabilities		 0.78 3.63 0.54 29 42 14 34 41 33 18 11
Noncurrent Deferred & Payable Income Tax Liabilities		 - - - - - 0.00 5.49 0.25 0.11 0.12 0.19
Other Noncurrent Operating Liabilities		 0.00 0.10 0.05 29 42 13 21 17 8.70 13 11
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 9.86 3.17 10 15 43 205 478 364 338 349 372
Total Preferred & Common Equity		 8.51 3.17 10 15 43 205 478 364 338 349 372
Preferred Stock		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 8.51 3.17 10 15 43 205 478 364 338 349 372
Common Stock		 73 74 84 113 144 303 585 612 653 684 711
Retained Earnings		 -64 -71 -74 -98 -100 -97 -107 -247 -315 -335 -340
Accumulated Other Comprehensive Income / (Loss)		 - - - - - 0.00 -0.28 -0.68 -0.35 0.02 0.13

Quarterly Balance Sheets for BioLife Solutions

This table presents BioLife Solutions' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 488 446 433 411 402 375 382 395 387 392 401
Total Current Assets		 136 133 120 117 112 88 89 131 125 127 133
Cash & Equivalents		 27 19 21 19 30 22 24 67 32 29 23
Short-Term Investments		 35 36 25 22 16 12 10 22 50 49 58
Accounts Receivable		 32 30 27 25 19 18 18 9.17 10 11 13
Inventories, net		 34 41 39 43 43 32 32 28 28 28 33
Prepaid Expenses		 8.04 6.20 7.99 7.85 4.41 3.48 4.91 5.82 5.92 8.95 6.34
Plant, Property, & Equipment, net		 22 26 26 21 21 17 18 6.61 7.67 11 15
Total Noncurrent Assets		 330 288 287 273 269 270 275 257 254 254 253
Long-Term Investments		 5.07 7.09 6.91 6.23 5.07 3.68 5.88 20 18 19 30
Goodwill		 225 225 225 225 225 225 225 212 212 212 209
Intangible Assets		 74 31 29 22 20 19 18 8.86 8.15 7.45 3.93
Other Noncurrent Operating Assets		 25 25 25 20 19 22 25 16 15 15 10
Total Liabilities & Shareholders' Equity		 488 446 433 411 402 375 382 395 387 392 401
Total Liabilities		 79 88 81 79 68 54 56 43 40 38 29
Total Current Liabilities		 37 47 40 43 39 31 32 28 28 27 18
Short-Term Debt		 4.74 4.55 2.02 5.09 8.62 11 12 10 10 7.49 2.50
Accounts Payable		 13 16 11 12 4.98 4.21 3.84 3.30 3.21 2.89 3.75
Accrued Expenses		 16 20 19 17 17 8.31 8.64 8.21 9.31 11 7.58
Current Deferred & Payable Income Tax Liabilities		 - 4.59 4.99 5.47 5.40 4.86 4.35 3.93 3.58 3.68 2.11
Other Current Liabilities		 2.93 3.07 3.34 3.30 3.00 2.82 3.11 1.84 2.17 2.18 2.32
Total Noncurrent Liabilities		 42 41 41 37 30 23 24 15 12 11 10
Noncurrent Deferred & Payable Income Tax Liabilities		 0.39 0.26 0.26 0.29 0.19 0.19 0.10 0.13 0.18 0.19 0.20
Other Noncurrent Operating Liabilities		 18 17 16 14 13 11 15 12 12 11 10
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 408 358 352 332 333 321 325 353 347 354 372
Total Preferred & Common Equity		 408 358 352 332 333 321 325 353 347 354 372
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 408 358 352 332 333 321 325 353 347 354 372
Common Stock		 604 619 623 633 659 668 673 688 698 704 711
Retained Earnings		 -195 -261 -271 -300 -325 -346 -348 -336 -351 -351 -339
Accumulated Other Comprehensive Income / (Loss)		 -1.26 -0.53 -0.50 -0.66 -0.57 -0.56 -0.21 0.03 0.07 0.13 -0.12

Annual Metrics And Ratios for BioLife Solutions

This table displays calculated financial ratios and metrics derived from BioLife Solutions' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 4.17% 27.57% 33.97% 79.11% 38.64% 75.69% 147.79% -36.02% -0.50% 8.44% 28.89%
EBITDA Growth		 -67.94% 6.40% 81.86% -2,949.12% 159.33% -83.14% -1,006.34% 149.00% -155.43% 126.02% -357.75%
EBIT Growth		 -59.93% 2.90% 76.00% -2,014.18% 151.21% -120.95% -1,225.45% 84.97% -223.55% 61.04% -271.25%
NOPAT Growth		 -60.00% 3.30% 78.23% 446.78% -106.01% -2,736.82% -463.37% 83.15% -295.75% 69.59% -270.83%
Net Income Growth		 -51.34% -60.98% 68.72% -894.23% 93.37% 219.67% -549.22% -1,469.43% 51.36% 70.32% 77.23%
EPS Growth		 -12.90% -54.29% 61.11% -642.86% 94.23% 33.33% -283.33% -1,313.04% 52.31% 71.61% 77.27%
Operating Cash Flow Growth		 -57.29% 13.01% 113.98% 288.10% -48.34% 447.82% -169.12% -84.80% -47.24% 167.46% 138.58%
Free Cash Flow Firm Growth		 38.47% 64.58% 176.62% 1,725.58% -309.53% -42.89% -298.70% 127.23% -45.37% -103.96% -346.64%
Invested Capital Growth		 50.95% -23.70% -48.77% -1,056.89% 254.53% 223.47% 269.06% -22.46% -20.20% -1.19% 4.70%
Revenue Q/Q Growth		 2.37% 5.52% 8.73% 13.33% 11.58% 15.44% 23.38% -50.75% -43.72% -42.63% -3.92%
EBITDA Q/Q Growth		 -16.36% 16.42% 19.63% -1,029.67% 135.34% -93.09% -66.71% 111.20% 91.56% 104.30% 23.81%
EBIT Q/Q Growth		 -9.12% 13.76% 20.53% -1,119.70% 130.17% -108.61% -51.55% 95.39% 79.34% 85.24% 23.88%
NOPAT Q/Q Growth		 -8.66% 13.80% 27.92% 6.74% -113.90% -119.91% -59.07% 94.84% 73.66% 84.37% 17.24%
Net Income Q/Q Growth		 -8.83% -36.82% 54.46% -1,477.52% 94.82% -74.51% -321.32% -31.44% 33.48% 56.15% -43.33%
EPS Q/Q Growth		 -6.06% -45.95% 48.78% -4,000.00% 96.10% 66.67% 0.00% 0.00% 0.00% 56.44% -66.67%
Operating Cash Flow Q/Q Growth		 -13.03% 12.22% 169.86% -8.49% -56.69% 96.31% -194.05% 50.42% -79.78% -7.32% 19.42%
Free Cash Flow Firm Q/Q Growth		 22.01% 63.73% -5.87% -46.39% 1.38% -34.59% 9.78% 419.61% 1,279.40% 92.59% -179.01%
Invested Capital Q/Q Growth		 9.11% -34.31% -46.19% 49.28% 132.20% 52.06% -1.44% -12.76% -17.41% -16.83% -2.33%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 59.15% 58.09% 61.20% 68.51% 68.00% 57.07% 31.09% 61.53% 60.55% 65.25% 64.56%
EBITDA Margin		 -72.71% -53.35% -7.22% -122.94% 52.61% 5.05% -18.47% 14.14% -7.88% 1.89% -11.26%
Operating Margin		 -77.80% -58.97% -9.58% 18.55% -0.80% -12.98% -29.51% -7.77% -30.90% -8.67% -17.26%
EBIT Margin		 -77.46% -58.96% -10.56% -124.65% 46.04% -5.49% -29.37% -6.90% -22.44% -8.06% -15.37%
Profit (Net Income) Margin		 -77.46% -97.74% -22.82% -126.66% -6.05% 4.12% -7.48% -183.38% -89.65% -24.54% -4.78%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 51.81% -154.80% 30.69% 2,883.77% 368.16% 176.67% 38.03%
Interest Burden Percent		 100.00% 165.79% 216.07% 101.61% -25.38% 48.52% 82.95% 92.15% 108.51% 172.27% 81.70%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -70.01% -63.84% -21.23% 0.00% -2.50% -5.91% -9.30% -1.12% -5.65% -1.95% -4.63%
ROIC Less NNEP Spread (ROIC-NNEP)		 -48.45% 325.47% 35.19% 0.00% 4.06% -18.49% -29.69% 262.62% 79.47% 15.49% -11.05%
Return on Net Nonoperating Assets (RNNOA)		 28.03% -59.63% -16.71% 0.00% -3.20% 7.51% 6.69% -32.08% -13.73% -3.93% 3.36%
Return on Equity (ROE)		 -41.99% -123.47% -37.94% -202.27% -5.71% 1.59% -2.61% -33.20% -19.38% -5.88% -1.28%
Cash Return on Invested Capital (CROIC)		 -110.62% -36.95% 43.26% 0.00% -165.15% -111.46% -124.02% 24.17% 16.82% -0.76% -9.23%
Operating Return on Assets (OROA)		 -35.13% -47.80% -11.60% -85.43% 18.23% -1.61% -8.87% -1.05% -3.95% -1.63% -3.67%
Return on Assets (ROA)		 -35.13% -79.24% -25.06% -86.81% -2.40% 1.21% -2.26% -27.84% -15.76% -4.97% -1.14%
Return on Common Equity (ROCE)		 -35.84% -110.67% -37.94% -202.27% -5.71% 1.59% -2.61% -33.20% -19.38% -5.88% -1.28%
Return on Equity Simple (ROE_SIMPLE)		 -58.71% -253.98% -24.92% -170.89% -3.81% 0.97% -1.86% -38.39% -20.14% -5.78% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.51 -3.40 -0.74 2.56 -0.15 -4.37 -25 -4.15 -16 -4.99 -12
NOPAT Margin		 -54.46% -41.28% -6.71% 12.98% -0.56% -9.09% -20.66% -5.44% -21.63% -6.07% -12.08%
Net Nonoperating Expense Percent (NNEP)		 -21.56% -389.31% -56.42% -122.70% -6.57% 12.58% 20.39% -263.74% -85.12% -17.44% 6.42%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -1.06% -4.54% -1.37% -3.08%
Cost of Revenue to Revenue		 40.86% 41.91% 38.80% 31.49% 32.00% 42.93% 68.91% 38.47% 39.45% 34.75% 35.44%
SG&A Expenses to Revenue		 75.50% 55.82% 41.04% 30.14% 32.49% 31.76% 28.26% 43.62% 57.04% 49.29% 47.31%
R&D to Revenue		 21.38% 24.66% 10.82% 6.57% 11.57% 13.97% 9.92% 11.37% 15.92% 9.62% 7.86%
Operating Expenses to Revenue		 136.94% 117.06% 70.79% 49.96% 68.80% 70.04% 60.60% 69.30% 91.45% 73.92% 81.82%
Earnings before Interest and Taxes (EBIT)		 -5.00 -4.85 -1.16 -25 13 -2.64 -35 -5.26 -17 -6.63 -15
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.69 -4.39 -0.80 -24 14 2.43 -22 11 -5.98 1.56 -11
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.12 6.55 8.10 15.21 7.62 6.36 3.25 2.14 2.12 3.45 3.13
Price to Tangible Book Value (P/TBV)		 4.22 6.55 8.10 15.21 0.00 11.28 15.34 7.25 6.31 9.48 7.32
Price to Revenue (P/Rev)		 4.12 2.52 7.42 11.27 12.09 27.16 13.03 10.21 9.43 14.64 12.10
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 658.52 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.15% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 3.99 4.82 31.39 0.00 9.24 10.75 3.58 2.28 2.68 4.36 4.09
Enterprise Value to Revenue (EV/Rev)		 3.74 2.70 6.72 9.39 11.78 25.23 12.51 9.67 9.09 13.49 10.90
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 22.39 499.76 0.00 68.36 0.00 713.79 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 25.58 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 72.31 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 122.40 78.94 265.74 182.61 0.00 0.00 0.00 131.65 52.15
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 49.17 6.74 0.00 0.00 0.00 8.25 14.12 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.90 0.00 0.00 0.01 0.02 0.03 0.08 0.07 0.05 0.01
Long-Term Debt to Equity		 0.00 0.90 0.00 0.00 0.00 0.00 0.01 0.07 0.05 0.01 0.00
Financial Leverage		 -0.58 -0.18 -0.47 -1.82 -0.79 -0.41 -0.23 -0.12 -0.17 -0.25 -0.30
Leverage Ratio		 1.20 1.56 1.51 2.33 2.38 1.32 1.15 1.19 1.23 1.18 1.12
Compound Leverage Factor		 1.20 2.58 3.27 2.37 -0.60 0.64 0.96 1.10 1.33 2.04 0.91
Debt to Total Capital		 0.00% 47.32% 0.00% 0.00% 0.86% 1.87% 2.57% 7.11% 6.60% 4.37% 1.33%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.86% 1.55% 1.22% 1.01% 1.74% 3.00% 1.33%
Long-Term Debt to Total Capital		 0.00% 47.32% 0.00% 0.00% 0.00% 0.32% 1.35% 6.10% 4.86% 1.37% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 13.70% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 86.30% 52.68% 100.00% 100.00% 99.14% 98.13% 97.43% 92.89% 93.40% 95.63% 98.67%
Debt to EBITDA		 0.00 -0.65 0.00 0.00 0.03 1.61 -0.57 2.59 -3.99 10.25 -0.46
Net Debt to EBITDA		 0.00 -0.33 0.00 0.00 -0.60 -38.06 2.80 -3.83 4.34 -60.62 10.63
Long-Term Debt to EBITDA		 0.00 -0.65 0.00 0.00 0.00 0.27 -0.30 2.22 -2.94 3.21 0.00
Debt to NOPAT		 0.00 -0.84 0.00 0.00 -2.45 -0.90 -0.51 -6.72 -1.45 -3.19 -0.43
Net Debt to NOPAT		 0.00 -0.42 0.00 0.00 55.66 21.15 2.50 9.95 1.58 18.89 9.91
Long-Term Debt to NOPAT		 0.00 -0.84 0.00 0.00 0.00 -0.15 -0.27 -5.77 -1.07 -1.00 0.00
Altman Z-Score		 -1.23 -10.41 16.82 0.89 3.47 26.58 12.13 5.04 4.93 13.61 19.83
Noncontrolling Interest Sharing Ratio		 14.64% 10.37% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.04 4.08 6.56 19.37 3.14 7.37 2.95 3.11 2.86 4.54 5.94
Quick Ratio		 2.75 2.29 5.08 17.38 1.54 6.32 2.18 2.17 1.23 3.48 4.22
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -5.55 -1.97 1.51 27 -58 -82 -328 89 49 -1.93 -23
Operating Cash Flow to CapEx		 -350.84% -344.17% 420.14% 469.60% 179.70% 345.02% -54.81% -81.73% -195.86% 261.26% 212.23%
Free Cash Flow to Firm to Interest Expense		 0.00 -4.85 4.35 5,499.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 -10.68 1.75 469.60 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 -13.78 1.33 369.60 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.45 0.81 1.10 0.69 0.40 0.29 0.30 0.15 0.18 0.20 0.24
Accounts Receivable Turnover		 7.04 7.75 9.95 9.71 6.52 7.20 7.63 2.67 3.63 9.64 11.71
Inventory Turnover		 1.88 1.92 2.37 2.32 1.21 1.83 4.11 0.93 0.96 1.02 1.15
Fixed Asset Turnover		 4.16 6.25 9.61 16.28 7.94 6.13 8.58 3.69 5.17 13.97 9.30
Accounts Payable Turnover		 3.50 3.96 6.10 8.81 4.56 6.08 8.82 1.94 3.39 9.78 14.07
Days Sales Outstanding (DSO)		 51.81 47.09 36.67 37.59 55.94 50.67 47.82 136.81 100.65 37.87 31.16
Days Inventory Outstanding (DIO)		 193.94 190.13 153.85 157.23 301.69 199.54 88.79 393.58 378.56 358.69 316.70
Days Payable Outstanding (DPO)		 104.18 92.09 59.83 41.42 79.98 60.03 41.38 188.62 107.57 37.31 25.94
Cash Conversion Cycle (CCC)		 141.57 145.13 130.70 153.39 277.65 190.18 95.23 341.77 371.64 359.24 321.92
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 6.03 4.60 2.36 -23 35 113 416 323 258 255 257
Invested Capital Turnover		 1.29 1.55 3.17 -1.95 4.45 0.65 0.45 0.21 0.26 0.32 0.38
Increase / (Decrease) in Invested Capital		 2.04 -1.43 -2.25 -25 57 78 304 -94 -65 -3.06 12
Enterprise Value (EV)		 24 22 74 185 322 1,213 1,491 737 690 1,110 1,049
Market Capitalization		 27 21 82 223 331 1,306 1,552 778 716 1,204 1,164
Book Value per Share		 $0.69 $0.25 $0.74 $0.79 $2.12 $6.27 $11.48 $8.52 $7.67 $7.52 $7.72
Tangible Book Value per Share		 $0.51 $0.25 $0.74 $0.79 ($0.59) $3.54 $2.43 $2.51 $2.57 $2.74 $3.30
Total Capital		 9.86 6.01 10 15 44 209 491 392 362 365 377
Total Debt		 0.00 2.84 0.00 0.00 0.38 3.92 13 28 24 16 5.00
Total Long-Term Debt		 0.00 2.84 0.00 0.00 0.00 0.67 6.64 24 18 5.00 0.00
Net Debt		 -3.82 1.44 -7.73 -37 -8.57 -92 -62 -41 -26 -94 -115
Capital Expenditures (CapEx)		 1.42 1.26 0.14 0.50 0.68 1.93 8.38 10 6.38 3.23 9.48
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 1.42 2.09 1.76 4.97 10 12 20 35 41 22 30
Debt-free Net Working Capital (DFNWC)		 5.25 3.49 8.42 36 17 102 89 98 85 127 119
Net Working Capital (NWC)		 5.25 3.49 8.42 36 16 99 83 94 78 116 114
Net Nonoperating Expense (NNE)		 1.48 4.65 1.78 28 1.50 -6.35 -16 136 52 15 -7.03
Net Nonoperating Obligations (NNO)		 -3.82 1.44 -7.73 -37 -8.57 -92 -62 -41 -80 -94 -115
Total Depreciation and Amortization (D&A)		 0.31 0.46 0.37 0.34 1.80 5.07 13 16 11 8.19 3.95
Debt-free, Cash-free Net Working Capital to Revenue		 22.06% 25.39% 15.92% 25.16% 37.90% 24.82% 16.37% 46.03% 53.43% 27.22% 30.82%
Debt-free Net Working Capital to Revenue		 81.36% 42.48% 76.37% 180.45% 61.46% 212.93% 75.01% 128.31% 111.67% 154.36% 123.25%
Net Working Capital to Revenue		 81.36% 42.48% 76.37% 180.45% 60.08% 206.17% 69.98% 123.13% 103.39% 141.06% 118.05%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.35) ($0.54) ($0.21) $0.18 ($0.09) $0.09 ($0.20) ($3.29) ($1.52) ($0.44) ($0.09)
Adjusted Weighted Average Basic Shares Outstanding		 12.45M 13.00M 14.12M 16.26M 19.46M 33.40M 42.09M 42.48M 43.72M 46.07M 47.75M
Adjusted Diluted Earnings per Share		 ($0.35) ($0.54) ($0.21) $0.14 ($0.09) ($0.03) ($0.20) ($3.29) ($1.52) ($0.44) ($0.10)
Adjusted Weighted Average Diluted Shares Outstanding		 12.45M 13.00M 14.12M 21.63M 19.46M 33.40M 42.09M 43.21M 43.72M 46.07M 48.65M
Adjusted Basic & Diluted Earnings per Share		 ($0.35) ($0.54) ($0.21) $0.00 ($0.09) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 12.18M 12.64M 13.26M 18.65M 19.46M 27.31M 38.50M 43.21M 45.30M 47M 48.30M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.51 -3.40 -0.74 2.56 0.54 -2.80 -21 -7.47 -18 -4.99 -12
Normalized NOPAT Margin		 -54.46% -41.28% -6.71% 12.98% 1.97% -5.82% -18.01% -9.80% -23.65% -6.07% -12.08%
Pre Tax Income Margin		 -77.46% -97.74% -22.82% -126.66% -11.68% -2.66% -24.36% -6.36% -24.35% -13.89% -12.56%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 -11.97 -3.36 -4,921.80 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 -8.38 -2.14 512.68 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 -15.08 -3.78 -5,021.80 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 -11.49 -2.55 412.68 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% -4.21% -1.74% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -1.39% -6.28% -1.74% 0.00% 312.66% -1.63% -0.09% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for BioLife Solutions

This table displays calculated financial ratios and metrics derived from BioLife Solutions' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - - 48,300,000.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 48,300,000.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 0.02
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -42.15% 64.47% -15.85% -3.11% 29.69% 42.88% 29.88% 28.94% 31.21% 24.34% 24.69%
EBITDA Growth		 -68.39% -79.97% 25.18% 76.04% 106.23% -51.61% 117.34% -1,527.20% -31.83% 33.85% -11.01%
EBIT Growth		 -31.40% -81.76% 25.19% 47.14% 90.39% -55.15% 63.35% -1,313.45% 160.75% 368.33% 152.01%
NOPAT Growth		 -31.81% -81.80% 25.56% 73.70% 89.93% -54.60% 63.03% -1,174.35% 73.13% 175.61% 105.41%
Net Income Growth		 -182.37% 69.59% 25.47% -103.15% 94.15% 183.30% 95.62% 23.56% 136.47% -11.15% 364.73%
EPS Growth		 -179.17% 0.00% 31.25% -95.65% 94.03% 181.82% 95.45% 26.67% 125.00% -14.81% 0.00%
Operating Cash Flow Growth		 -392.71% -70.59% -65.01% 183.69% 209.66% -28.82% 138.59% 14.07% 27.11% 198.85% -128.43%
Free Cash Flow Firm Growth		 7.20% -55.62% -90.24% -50.63% -89.99% -87.10% 269.20% 92.05% 681.61% -177.59% -112.29%
Invested Capital Growth		 -15.71% -20.20% -4.94% -6.20% -1.87% -1.19% -16.69% -15.93% -14.16% 4.70% 2.45%
Revenue Q/Q Growth		 -19.37% -162.18% -26.22% -10.71% 7.92% -127.39% 385.97% 6.18% 10.41% -33.07% 46.39%
EBITDA Q/Q Growth		 -506.32% 252.61% 49.42% 93.77% 257.53% 1,086.26% -98.19% -9,376.83% 108.54% 124.15% -73.10%
EBIT Q/Q Growth		 -197.13% 208.65% 43.73% 72.57% 46.00% 607.24% -115.01% -1,370.49% 101.19% 1,196.92% -91.81%
NOPAT Q/Q Growth		 -45.61% 252.32% 43.13% 72.40% 44.22% 786.38% -111.38% -1,266.42% 99.33% 1,902.83% -98.19%
Net Income Q/Q Growth		 -185.64% 48.66% 23.62% -102.71% 91.78% 831.59% -103.60% -3,435.27% 103.92% 1,682.61% -89.29%
EPS Q/Q Growth		 -191.30% 50.75% 26.67% -104.55% 91.11% 775.00% -103.70% -3,200.00% 103.03% 2,200.00% -91.30%
Operating Cash Flow Q/Q Growth		 43.26% 152.77% -293.64% 244.34% -25.65% -65.74% 4.98% 326.64% -17.16% -19.46% -109.99%
Free Cash Flow Firm Q/Q Growth		 28.05% 72.73% 159.34% 104.32% -74.03% 122.65% 380.00% -26.84% 16.82% -123.38% 38.04%
Invested Capital Q/Q Growth		 -4.25% -17.41% 0.46% -0.90% 0.17% -16.83% 0.90% 0.01% 2.28% -2.33% 2.54%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 50.88% 0.00% 39.59% 52.57% 53.30% 0.00% 65.94% 64.64% 63.85% 63.76% 63.62%
EBITDA Margin		 -52.06% 0.00% -24.54% -1.71% 2.50% 0.00% 0.69% -59.85% 4.63% 15.51% 2.85%
Operating Margin		 -65.65% 0.00% -31.92% -9.87% -5.10% 0.00% -5.09% -65.47% -0.32% 7.18% 0.10%
EBIT Margin		 -64.65% 0.00% -31.15% -9.57% -4.79% 0.00% -4.66% -64.50% 0.69% 13.46% 0.75%
Profit (Net Income) Margin		 -123.58% 0.00% -32.22% -73.14% -5.57% 0.00% -1.87% -62.30% 2.21% 58.93% 4.31%
Tax Burden Percent		 185.68% -91.45% 101.30% 289.94% 98.38% 165.19% 103.23% 100.80% 88.34% 329.27% 95.03%
Interest Burden Percent		 102.95% 98.78% 102.09% 263.59% 118.24% 101.56% 38.92% 95.83% 360.51% 132.94% 602.90%
Effective Tax Rate		 0.00% -1.42% 0.00% 0.00% 0.00% -1.87% 0.00% 0.00% 11.66% -5.15% 4.97%
Return on Invested Capital (ROIC)		 -18.16% 0.00% -9.70% -2.98% -1.66% 0.00% -1.11% -15.23% -0.10% 2.89% 0.04%
ROIC Less NNEP Spread (ROIC-NNEP)		 44.82% 0.00% 0.98% 86.23% 1.46% 0.00% -1.78% -7.32% -1.37% -5.93% -1.10%
Return on Net Nonoperating Assets (RNNOA)		 -3.52% 0.00% -0.08% -5.38% -0.09% 0.00% 0.31% 1.16% 0.22% 1.80% 0.31%
Return on Equity (ROE)		 -21.68% 0.00% -9.78% -8.37% -1.74% 0.00% -0.79% -14.07% 0.12% 4.69% 0.35%
Cash Return on Invested Capital (CROIC)		 -1.21% 16.82% -9.84% -6.80% -8.44% -0.76% 16.96% 12.23% 10.30% -9.23% -6.75%
Operating Return on Assets (OROA)		 -19.39% 0.00% -10.09% -3.23% -1.73% 0.00% -1.03% -15.82% 0.18% 3.22% 0.19%
Return on Assets (ROA)		 -37.06% 0.00% -10.43% -24.69% -2.02% 0.00% -0.41% -15.28% 0.57% 14.08% 1.10%
Return on Common Equity (ROCE)		 -21.68% 0.00% -9.78% -8.37% -1.74% 0.00% -0.79% -14.07% 0.12% 4.69% 0.35%
Return on Equity Simple (ROE_SIMPLE)		 -30.79% 0.00% -18.88% -22.85% -14.14% 0.00% -2.95% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -11 16 -7.09 -1.96 -1.09 7.49 -0.85 -12 -0.08 1.42 0.03
NOPAT Margin		 -45.95% 0.00% -22.35% -6.91% -3.57% 0.00% -3.56% -45.83% -0.28% 7.55% 0.09%
Net Nonoperating Expense Percent (NNEP)		 -62.98% -51.90% -10.68% -89.22% -3.11% 5.70% 0.67% -7.90% 1.27% 8.82% 1.13%
Return On Investment Capital (ROIC_SIMPLE)		 - 4.56% - - - 2.05% -0.23% -3.26% -0.02% 0.38% 0.01%
Cost of Revenue to Revenue		 49.12% 0.00% 60.41% 47.43% 46.70% 0.00% 34.06% 35.36% 36.15% 36.24% 36.38%
SG&A Expenses to Revenue		 45.87% 0.00% 40.77% 38.46% 37.13% 0.00% 48.04% 44.83% 43.02% 56.16% 44.39%
R&D to Revenue		 15.86% 0.00% 11.14% 8.41% 6.71% 0.00% 9.21% 10.70% 9.65% -0.35% 9.64%
Operating Expenses to Revenue		 116.53% 0.00% 71.51% 62.44% 58.40% 0.00% 71.02% 130.11% 64.17% 56.59% 63.52%
Earnings before Interest and Taxes (EBIT)		 -15 17 -9.88 -2.71 -1.46 7.43 -1.12 -16 0.20 2.53 0.21
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -12 19 -7.79 -0.49 0.76 9.06 0.16 -15 1.30 2.91 0.78
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.81 2.12 2.52 3.07 3.55 3.45 3.04 2.95 3.45 3.13 2.48
Price to Tangible Book Value (P/TBV)		 7.05 6.31 9.50 12.75 14.04 9.48 8.17 8.09 9.12 7.32 5.77
Price to Revenue (P/Rev)		 4.46 9.43 6.12 7.23 8.06 14.64 12.23 10.96 12.20 12.10 9.07
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1.86 2.68 2.64 3.18 3.71 4.36 3.81 3.64 4.30 4.09 3.09
Enterprise Value to Revenue (EV/Rev)		 4.31 9.09 5.94 7.12 7.92 13.49 11.14 10.00 11.30 10.90 7.99
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 713.79 366.90 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 124.88 131.65 66.82 60.11 67.15 52.15 45.40
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 14.12 0.00 0.00 0.00 0.00 20.40 27.15 38.60 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.08 0.07 0.08 0.07 0.06 0.05 0.04 0.03 0.02 0.01 0.01
Long-Term Debt to Equity		 0.07 0.05 0.05 0.04 0.03 0.01 0.01 0.00 0.00 0.00 0.00
Financial Leverage		 -0.08 -0.17 -0.08 -0.06 -0.06 -0.25 -0.18 -0.16 -0.16 -0.30 -0.28
Leverage Ratio		 1.21 1.23 1.23 1.20 1.21 1.18 1.16 1.14 1.14 1.12 1.10
Compound Leverage Factor		 1.25 1.21 1.25 3.16 1.43 1.20 0.45 1.09 4.11 1.49 6.62
Debt to Total Capital		 7.59% 6.60% 7.08% 6.42% 6.05% 4.37% 3.54% 2.81% 2.07% 1.33% 0.67%
Short-Term Debt to Total Capital		 1.42% 1.74% 2.40% 3.09% 3.53% 3.00% 2.86% 2.81% 2.07% 1.33% 0.67%
Long-Term Debt to Total Capital		 6.18% 4.86% 4.67% 3.33% 2.52% 1.37% 0.68% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 92.41% 93.40% 92.92% 93.58% 93.95% 95.63% 96.46% 97.19% 97.93% 98.67% 99.33%
Debt to EBITDA		 -0.39 -3.99 -0.50 -0.45 -0.58 10.25 4.86 -0.74 -0.53 -0.46 -0.23
Net Debt to EBITDA		 0.28 4.34 0.49 0.32 0.53 -60.62 -35.90 6.62 6.39 10.63 9.97
Long-Term Debt to EBITDA		 -0.31 -2.94 -0.33 -0.23 -0.24 3.21 0.94 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.44 -1.45 -0.54 -0.53 -0.66 -3.19 -3.66 -0.70 -0.53 -0.43 -0.22
Net Debt to NOPAT		 0.32 1.58 0.53 0.38 0.60 18.89 27.06 6.32 6.47 9.91 9.69
Long-Term Debt to NOPAT		 -0.36 -1.07 -0.36 -0.27 -0.27 -1.00 -0.71 0.00 0.00 0.00 0.00
Altman Z-Score		 3.95 5.20 6.74 10.29 11.60 13.73 14.49 14.47 18.43 19.97 18.70
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.74 2.86 2.89 2.86 2.78 4.54 4.73 4.43 4.66 5.94 7.30
Quick Ratio		 1.54 1.23 1.65 1.69 1.62 3.48 3.53 3.24 3.31 4.22 5.15
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 47 82 8.93 18 4.74 11 51 37 43 -10 -6.27
Operating Cash Flow to CapEx		 -292.71% 235.58% -1,257.02% 649.15% 431.06% 215.88% 986.86% 422.72% 184.86% 115.45% -294.01%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.30 0.18 0.32 0.34 0.36 0.20 0.22 0.25 0.26 0.24 0.26
Accounts Receivable Turnover		 4.73 3.63 5.61 6.07 6.75 9.64 6.33 6.65 6.96 11.71 9.15
Inventory Turnover		 2.17 0.96 2.17 2.43 2.38 1.02 0.86 1.10 1.19 1.15 1.22
Fixed Asset Turnover		 6.31 5.17 5.82 6.37 7.41 13.97 6.35 7.50 6.95 9.30 9.63
Accounts Payable Turnover		 6.67 3.39 8.97 11.71 11.37 9.78 7.38 8.90 10.63 14.07 10.46
Days Sales Outstanding (DSO)		 77.18 100.65 65.02 60.11 54.06 37.87 57.69 54.91 52.41 31.16 39.90
Days Inventory Outstanding (DIO)		 168.03 378.56 168.07 149.93 153.26 358.69 424.08 332.58 306.13 316.70 299.16
Days Payable Outstanding (DPO)		 54.74 107.57 40.67 31.17 32.10 37.31 49.48 41.01 34.32 25.94 34.90
Cash Conversion Cycle (CCC)		 190.46 371.64 192.41 178.88 175.23 359.24 432.29 346.48 324.21 321.92 304.16
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 312 258 308 306 306 255 257 257 263 257 263
Invested Capital Turnover		 0.40 0.26 0.43 0.43 0.46 0.32 0.31 0.33 0.35 0.38 0.39
Increase / (Decrease) in Invested Capital		 -58 -65 -16 -20 -5.83 -3.06 -51 -49 -43 12 6.29
Enterprise Value (EV)		 581 690 815 971 1,136 1,110 978 934 1,131 1,049 813
Market Capitalization		 601 716 840 986 1,155 1,204 1,073 1,024 1,222 1,164 922
Book Value per Share		 $7.63 $7.67 $7.36 $6.98 $7.05 $7.52 $7.50 $7.30 $7.38 $7.72 $7.71
Tangible Book Value per Share		 $1.96 $2.57 $1.95 $1.68 $1.78 $2.74 $2.80 $2.66 $2.80 $3.30 $3.31
Total Capital		 359 362 359 344 346 365 366 357 361 377 375
Total Debt		 27 24 25 22 21 16 13 10 7.49 5.00 2.50
Total Long-Term Debt		 22 18 17 11 8.74 5.00 2.50 0.00 0.00 0.00 0.00
Net Debt		 -20 -26 -25 -16 -19 -94 -96 -90 -91 -115 -109
Capital Expenditures (CapEx)		 1.50 0.98 0.36 1.00 1.11 0.76 0.18 1.74 3.30 4.26 0.17
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 38 41 36 34 35 22 25 25 28 30 36
Debt-free Net Working Capital (DFNWC)		 79 85 82 68 69 127 114 107 107 119 117
Net Working Capital (NWC)		 74 78 73 57 57 116 103 97 99 114 115
Net Nonoperating Expense (NNE)		 18 31 3.13 19 0.61 -4.97 -0.40 4.19 -0.70 -9.65 -1.16
Net Nonoperating Obligations (NNO)		 -20 -80 -25 -16 -19 -94 -96 -90 -91 -115 -109
Total Depreciation and Amortization (D&A)		 2.97 2.17 2.10 2.23 2.23 1.64 1.28 1.18 1.11 0.39 0.58
Debt-free, Cash-free Net Working Capital to Revenue		 28.36% 53.43% 26.48% 24.80% 24.46% 27.22% 28.80% 27.18% 27.92% 30.82% 35.88%
Debt-free Net Working Capital to Revenue		 58.83% 111.67% 59.48% 49.85% 48.44% 154.36% 129.73% 114.66% 106.76% 123.25% 115.55%
Net Working Capital to Revenue		 55.06% 103.39% 53.20% 42.07% 39.90% 141.06% 117.83% 103.91% 99.28% 118.05% 113.09%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.67) ($0.33) ($0.22) ($0.45) ($0.04) $0.27 ($0.01) ($0.33) $0.01 $0.24 $0.02
Adjusted Weighted Average Basic Shares Outstanding		 43.57M 43.72M 45.43M 25.29M 46.18M 46.07M 46.69M 31.96M 47.93M 47.75M 48.46M
Adjusted Diluted Earnings per Share		 ($0.67) ($0.33) ($0.22) ($0.45) ($0.04) $0.27 ($0.01) ($0.33) $0.01 $0.23 $0.02
Adjusted Weighted Average Diluted Shares Outstanding		 43.57M 43.72M 45.43M 46.00M 46.18M 46.07M 47.13M 31.96M 48.72M 48.65M 49.25M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 44.03M 45.30M 46.03M 46.14M 46.39M 47M 47.56M 47.91M 48.15M 48.30M 48.86M
Normalized Net Operating Profit after Tax (NOPAT)		 -6.12 11 -6.92 -1.96 -1.09 5.15 -0.85 -12 -0.08 0.94 0.03
Normalized NOPAT Margin		 -25.97% 0.00% -21.82% -6.91% -3.57% 0.00% -3.56% -45.83% -0.28% 5.02% 0.09%
Pre Tax Income Margin		 -66.56% 0.00% -31.80% -25.23% -5.66% 0.00% -1.81% -61.81% 2.50% 17.90% 4.54%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Here is a concise, data-driven read on BioLife Solutions (BLFS) using the last four years of quarterly statements. The focus is on cash flow, liquidity, earnings volatility, and balance-sheet posture.

  • Strong operating cash flow recently: Net Cash From Continuing Operating Activities was about $6.10 million in Q3 2025 and $4.92 million in Q4 2025, supporting liquidity and funding optionality. (Q3 2025: $6,104,000; Q4 2025: $4,916,000)
  • No long-term debt on the balance sheet: Long-Term Debt is shown as $0.0 in Q3 2025, reducing leverage risk.
  • Solid liquidity position: Cash & Equivalents plus Short-Term Investments totaled about $78.95 million in Q3 2025 (Cash $29.48m + Short-Term Investments $49.47m), with Total Current Assets around $126.57 million.
  • Healthy gross margin in Q4 2025: Total Gross Profit $11.978 million on Revenue $18.785 million, roughly 63.8% gross margin.
  • High goodwill and intangible asset levels on the balance sheet: Goodwill about $212.304 million and Intangible Assets about $7.45 million in Q3 2025, signaling an acquisitions-heavy asset base with potential impairment risks if growth slows.
  • Discontinued operations contributed to Q4 2025 net income: $7.535 million from discontinued operations; this boosts quarterly earnings but may not reflect ongoing operations.
  • Earnings from continuing operations have been volatile across recent quarters: Q1 2025 continuing net income about -$4.48 million; Q2 2025 about -$15.84 million; Q3 2025 about +$0.62 million; Q4 2025 about +$3.54 million (approx for continuing ops in Q4).
  • Big impairment hit in 2025 Q2: Impairment expense of $69.9 million weighed on profitability.
  • Material investing cash outflows in 2025: notable cash outlays for investing activities (e.g., around $36.7 million invested in Q4 2025; about $33.98 million invested in Q2 2025), pressuring free cash flow.
  • Occasional continued-op earnings weakness: several quarters show negative net income from continuing operations (e.g., Q1 2025 around -$4.48 million; Q2 2025 around -$15.84 million), highlighting ongoing profitability challenges outside one-off items.
05/27/26 01:27 PM ETAI Generated. May Contain Errors.

BioLife Solutions Financials - Frequently Asked Questions

According to the most recent income statement we have on file, BioLife Solutions' fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

BioLife Solutions' net income appears to be on an upward trend, with a most recent value of -$4.60 million in 2025, falling from -$5.00 million in 2015. The previous period was -$20.18 million in 2024. See where experts think BioLife Solutions is headed by visiting BioLife Solutions' forecast page.

BioLife Solutions' total operating income in 2025 was -$16.60 million, based on the following breakdown:
  • Total Gross Profit: $62.12 million
  • Total Operating Expenses: $78.72 million

Over the last 10 years, BioLife Solutions' total revenue changed from $6.45 million in 2015 to $96.21 million in 2025, a change of 1,391.9%.

BioLife Solutions' total liabilities were at $34.00 million at the end of 2025, a 32.8% decrease from 2024, and a 1,254.3% increase since 2015.

In the past 10 years, BioLife Solutions' cash and equivalents has ranged from $1.41 million in 2016 to $91.54 million in 2024, and is currently $33.04 million as of their latest financial filing in 2025.

Over the last 10 years, BioLife Solutions' book value per share changed from 0.69 in 2015 to 7.72 in 2025, a change of 1,011.5%.


Related Companies

Financial statements for NASDAQ:BLFS last updated on 5/12/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
SpaceX eyes a 1.75 trillion valuation - here's what to know
Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...
Brownstone Research | Sponsoredtc pixel
$30 stock to buy before Starlink goes public (WATCH NOW!)
In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...
Paradigm Press | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Read now. Do not delete. You’ve been warned.
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...
Porter & Company | Sponsoredtc pixel
SpaceX IPO hides a much bigger story
The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...
Weiss Ratings | Sponsoredtc pixel